Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRDN-003 in Active Thyroid Eye Disease (REVEAL-1)
NCT06625411Phase 3Active, not recruiting
- Sponsor
- Viridian Therapeutics
- Start
- Aug 2024
- Primary completion
- Feb 2026
- Countries
- 5
01
Overview
A Phase 3 trial of elegrobart in thyroid eye disease (TED), sponsored by Viridian Therapeutics. Started Aug 2024; status: active, not recruiting.
02
Drugs
elegrobart
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT06625411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06625411.